Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab Induction in Locally Advanced NSCLC
NCT05766800Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Mar 2023; status: recruiting.
02
Drugs
serplulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05766800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05766800.